First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase...

Related Keywords

United Kingdom ,Belgium ,Canada ,Melbourne ,Victoria ,Australia ,Japan ,Dingwei ,Fujian ,China ,United States ,Switzerland ,Chinese ,Australian ,Telix Asia Pacific ,Cdx Illuccix ,Kyahn Williamson ,Corporate Communications ,Health Canada ,Telix Pharmaceuticals ,Zhongnan Hospital Of Wuhan University ,Telix Pharmaceuticals Limited Disclosure Committee ,European Union ,Prnewswire Telix Pharmaceuticals Limited ,Drug Administration ,Australian Therapeutic Goods Administration ,Group Limited Grand Pharma ,Linkedin ,Australian Securities Exchange ,Pharmaceuticals Limited ,United States Food ,Greater China ,Grand Pharmaceutical Group Limited ,Grand Pharma ,Regional Medical Director ,Zhongnan Hospital ,Wuhan University ,Prostate Cancer ,Asia Pacific ,Telix Pharmaceuticals Limited ,Biotechnology ,Health Care Amp Hospitals ,Pharmaceuticals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Surveys ,Olls And Research ,